Furthermore, the study highlights the importance of investigating the functional roles of underexplored fusions, such as CCDC32/CBX3, in AML progression, as these may reveal therapeutic vulnerabilities, including targeting wild-type CBX3 overexpression during relapse. This evidence concerns the gene CBX3 and acute myeloid leukemia.